ArticleScientific reports2026
Bridging in vitro bioactivities and in silico insights of Rubia cordifolia L. (Rubiaceae) leaf extracts for therapeutic applications.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinal plants are important sources of bioactive compounds with significant therapeutic potential. This study evaluated the phenolic profile, biological activities, and molecular docking-based antiproliferative potential of the Rubia cordifolia leaf extracts in methanolic (RCLM), chloroform (RCLC), and distilled water (RCLD). Leaf extract was selected because of its richness in secondary metabolites and its roles in photosynthesis, defense mechanisms, and environmental interactions. Phytochemical screening was performed using High-Performance Liquid Chromatography (HPLC), while antioxidant activity was determined through DPPH scavenging, total antioxidant capacity (TAC), and total reducing power (TRP). Antibacterial activity was evaluated against Staphylococcus aureus, Listeria monocytogenes, and Bacillus subtilis. Cytotoxicity was investigated using the brine shrimp lethality assay and PC3 and 3T3 cell lines. Among the extracts, RCLM exhibited the strongest antioxidant activity with a DPPH IC50 of 54.41 ± 0.53 µg/mL, a TAC of 102.08 ± 0.89 µg/mL, and a TRP of 201.56 ± 0.61 µg/mL. The highest antibacterial activity was observed against Bacillus subtilis with an inhibition zone of 26 ± 0.7 mm. The methanolic extract also showed pronounced brine shrimp cytotoxic activity. Furthermore, RCLM showed > 50% inhibition against 3T3 cell lines and < 50% inhibition against PC3 cell lines. HPLC analysis revealed chlorogenic acid as the major phenolic compound (392.44 ppm), while salicylic acid was detected at the lowest concentration (3.408 ppm). Molecular docking demonstrated strong binding affinities for chlorogenic acid (- 7.7 kcal/mol) and HB acid (- 10.5 kcal/mol) to target proteins implicated in oxidative stress and cancer progression. These findings suggest that Rubia cordifolia leaf extract possesses promising pharmacological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.